| pubmed-article:15653751 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0385242 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0288331 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0597298 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C1332397 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C1522480 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C1413357 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0445450 | lld:lifeskim |
| pubmed-article:15653751 | lifeskim:mentions | umls-concept:C0337026 | lld:lifeskim |
| pubmed-article:15653751 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15653751 | pubmed:dateCreated | 2005-3-28 | lld:pubmed |
| pubmed-article:15653751 | pubmed:abstractText | A systematic study was undertaken to characterize the role of APO 2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (APO2L/TRAIL) and Fas ligand (FasL) together with the expression of several anti- or proapoptotic proteins in the down-regulation of normal human T cell responses. We have observed for the first time that the higher sensitivity of normal human T cell blasts to apoptosis and activation-induced cell death (AICD) as compared with naive T cells correlates with the increased expression of Bcl-x short (Bcl-xS) and Bim. T cell blasts die in the absence of interleukin 2 (IL-2) with no additional effect of death receptor ligation. In the presence of IL-2, recombinant APO2L/TRAIL or cytotoxic anti-Fas monoclonal antibodies induce rather inhibition of IL-2-dependent growth and not cell death on normal human T cell blasts. This observation is of physiological relevance, as supernatants from T cell blasts, pulse-stimulated with phytohemagglutinin (PHA) or through CD3 or CD59 ligation and containing bioactive APO2L/TRAIL and/or FasL expressed on microvesicles or direct CD3 or CD59 ligation, had the same effect. Cell death was only observed in the presence of cycloheximide or after a pulse through CD3 or CD59, correlating with a net reduction in cellular Fas-associated death domain-like IL-1beta-converting enzyme-inhibitory protein long (c-FLIPL) and c-FLIPS expression. We also show that death receptor and free radical generation contribute, at least partially, to AICD induced by PHA and also to the inhibition of IL-2-dependent cell growth by CD3 or CD59 ligation. Finally, we have also shown that T cell blasts surviving PHA-induced AICD are memory CD44high cells with increased c-FLIPS and Bcl-xL expression. | lld:pubmed |
| pubmed-article:15653751 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15653751 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15653751 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15653751 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15653751 | pubmed:issn | 0741-5400 | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:PardoJuliánJ | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:AnelAlbertoA | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:IturraldeMarí... | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:Martínez-Lore... | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:PiñeiroAndrés... | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:NavalJavierJ | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:AlavaMaría... | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:BosqueAlberto... | lld:pubmed |
| pubmed-article:15653751 | pubmed:author | pubmed-author:MarzoIsabelI | lld:pubmed |
| pubmed-article:15653751 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15653751 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:15653751 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15653751 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15653751 | pubmed:pagination | 568-78 | lld:pubmed |
| pubmed-article:15653751 | pubmed:dateRevised | 2007-9-28 | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:meshHeading | pubmed-meshheading:15653751... | lld:pubmed |
| pubmed-article:15653751 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15653751 | pubmed:articleTitle | Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. | lld:pubmed |
| pubmed-article:15653751 | pubmed:affiliation | Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Zaragoza, E-50009, Spain. | lld:pubmed |
| pubmed-article:15653751 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15653751 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:356 | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| entrez-gene:598 | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| entrez-gene:8743 | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| entrez-gene:10018 | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| entrez-gene:8837 | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15653751 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15653751 | lld:pubmed |
